Department of Neonatal Medicine, Xin-Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Endocrinology and Genetic Metabolism, Xin-Hua Hospital, Shanghai Institute of Pediatric Research Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Sci Rep. 2017 Jul 28;7(1):6762. doi: 10.1038/s41598-017-06462-y.
Molecular characterization of PAH deficiency has been proven essential in establishing treatment options. We examine the diagnostic accuracy of two genetic assays to predict BH4 responsiveness: to determine whether the AV sum test or mutation-status assessment test can obviate the need for BH4 loading in Chinese patients. The overall predicted response in 346 patients was 31.65% by the AV sum test and 25.43% by the other assay; both percentages were lower than 51.06% derived from loading results in 94 patients. Responders were compound heterozygotes with definite BH4 responsive mutations, while non-responders had null/null ones; some consistently with specific mutations and genotypes. The sensitivity and specificity of the assays were 81.1% and 92.5% for the AV sum, and 82.9%, 97.3% for the other. An AV sum cutoff >2 has a positive predictive value (PPV) of 90.9%, while the presence of at least one BH4 responsive mutation has a PPV of 97.1%. The two approaches showed good concordance. Our data confirmed that the mutation-status assessment has a higher diagnostic accuracy in predicting response for Chinese patients than the AV sum test. BH4-responsiveness may be predicted or excluded from patients' molecular characteristics to some extent, thus some patients may avoid the initial loading.
已证实,对苯丙氨酸羟化酶缺乏症进行分子特征分析对于确定治疗方案至关重要。我们检验了两种基因检测方法在预测 BH4 反应性方面的诊断准确性,以确定 AV 总和测试或突变状态评估测试是否可以避免对中国患者进行 BH4 负荷试验。在 346 名患者中,AV 总和测试的总体预测反应率为 31.65%,另一种检测方法为 25.43%;这两个百分比均低于 94 名患者进行负荷试验得出的 51.06%。反应者为具有明确 BH4 反应性突变的复合杂合子,而非反应者为纯合子/纯合子;某些患者与特定突变和基因型一致。对于 AV 总和,该检测的敏感性和特异性分别为 81.1%和 92.5%,对于另一种检测,分别为 82.9%和 97.3%。AV 总和>2 的截断值具有 90.9%的阳性预测值(PPV),而至少存在一种 BH4 反应性突变的存在具有 97.1%的 PPV。这两种方法具有良好的一致性。我们的数据证实,对于中国患者,突变状态评估在预测反应方面比 AV 总和测试具有更高的诊断准确性。在一定程度上,可根据患者的分子特征预测或排除 BH4 反应性,从而使某些患者避免初始负荷试验。